Terence Flynn: AI Opportunities in Healt...

From chocolate and sugar prices to energy markets and inflation, El Niño’s impacts may soon reach far beyond the weather forecast. Our Latin America Agribusiness Analyst Julia Rizzo maps out where the pressure could emerge first.Read more insights from Morgan Stanley.----- Transc ... Show More

After a historic rally and a sharp correction, South Korea’s equity market may be approaching a turning point. Our Chief Korea Equity Strategist, Joon Seok, explains that the next cycle will need stronger foundations and more sectors joining in.Read more insights from Morgan Stan ... Show More

Our analysts Andrew Ruben and Nathan Feather discuss how AI shopping agents could transform how consumers discover, compare and buy products and the implications for eCommerce.Read more insights from Morgan Stanley.----- Transcript -----Andrew Ruben: Welcome to Thoughts on the Ma ... Show More

<p>Today's guest is Nishtha Jain, Head of Innovation and Digital Technology at Takeda Pharmaceuticals. Nistha returns to the program to discuss the transformative impact of AI across the pharmaceutical value chain. She and Emerj Editorial Director Matthew DeMello explore how AI i ... Show More

Vaccine-maker Moderna is also a data company, and that’s enabling it to use AI to drastically reduce drug-development times, Chief Information Officer Brad Miller tells Bloomberg Intelligence’s Sam Fazeli and Mandeep Singh. This episode of the Tech Disruptors podcast looks at a w ... Show More

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ... Show More

Learn how agentic AI is transforming pharma. IQVIA’s Raja Shankar and Avinob Roy share how intelligent automation accelerates clinical trials, improves commercial strategy, and powers better patient care — turning healthcare data into outcomes at scale. Listen to the full archive ... Show More

<p><span data-preserver-spaces="true">Today's guest is Liran Belenzon, Co-founder and CEO of BenchSci. BenchSci is a global leader in AI solutions for preclinical R&D that helps decipher complex biomedical research using proprietary technology. Liran joins us to discuss how AI is ... Show More

The pharmaceutical industry has yet to develop highly effective treatments for common chronic and neurological issues, like Alzheimer’s and cardiovascular disease. But GenAI promises to accelerate the discovery and development of breakthrough treatments. BCG’s Priya Chandran expl ... Show More

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ... Show More

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ... Show More

Today's show: It's another blockbuster panel of insiders, as Alex sits down with Astasia Myers from Felicis, Matt Turck from First Mark Capital, and D.A. Wallach of Time BioVentures. AI is reshaping early-stage investing, with startups raising record-setting rounds adn chasing $1 ... Show More